Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

BACKGROUND: The clinical application of PD1/PD-L1 targeting checkpoint inhibitors in colorectal cancer (CRC) has largely focused on a subset of microsatellite instable (MSI-high) patients. However, the proposed genotype that sensitizes these patients to immunotherapy is not captured by MSI status al...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Gastrointest Oncol
Prif Awduron: Fabrizio, David A., George, Thomas J., Dunne, Richard F., Frampton, Garrett, Sun, James, Gowen, Kyle, Kennedy, Mark, Greenbowe, Joel, Schrock, Alexa B., Hezel, Aram F., Ross, Jeffrey S., Stephens, Phillip J., Ali, Siraj M., Miller, Vincent A., Fakih, Marwan, Klempner, Samuel J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AME Publishing Company 2018
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6087857/
https://ncbi.nlm.nih.gov/pubmed/30151257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.05.06
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg